Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women.

Importance Risk profiles for premature coronary heart disease (CHD) are unclear. Objective To examine baseline risk profiles for incident CHD in women by age at onset. Design, Setting, and Participants A prospective cohort of US female health professionals participating in the Women's Health Study was conducted; median follow-up was 21.4 years. Participants included 28 024 women aged 45 years or older without known cardiovascular disease. Baseline profiles were obtained from April 30, 1993, to January 24, 1996, and analyses were conducted from October 1, 2017, to October 1, 2020. Exposures More than 50 clinical, lipid, inflammatory, and metabolic risk factors and biomarkers. Main Outcomes and Measures Four age groups were examined (<55, 55 to <65, 65 to <75, and ≥75 years) for CHD onset, and adjusted hazard ratios (aHRs) were calculated using stratified Cox proportional hazard regression models with age as the time scale and adjusting for clinical factors. Women contributed to different age groups over time. Results Of the clinical factors in the women, diabetes had the highest aHR for CHD onset at any age, ranging from 10.71 (95% CI, 5.57-20.60) at CHD onset in those younger than 55 years to 3.47 (95% CI, 2.47-4.87) at CHD onset in those 75 years or older. Risks that were also noted for CHD onset in participants younger than 55 years included metabolic syndrome (aHR, 6.09; 95% CI, 3.60-10.29), hypertension (aHR, 4.58; 95% CI, 2.76-7.60), obesity (aHR, 4.33; 95% CI, 2.31-8.11), and smoking (aHR, 3.92; 95% CI, 2.32-6.63). Myocardial infarction in a parent before age 60 years was associated with 1.5- to 2-fold risk of CHD in participants up to age 75 years. From approximately 50 biomarkers, lipoprotein insulin resistance had the highest standardized aHR: 6.40 (95% CI, 3.14-13.06) for CHD onset in women younger than 55 years, attenuating with age. In comparison, weaker but significant associations with CHD in women younger than 55 years were noted (per SD increment) for low-density lipoprotein cholesterol (aHR, 1.38; 95% CI, 1.10-1.74), non-high-density lipoprotein cholesterol (aHR, 1.67; 95% CI, 1.36-2.04), apolipoprotein B (aHR, 1.89; 95% CI, 1.52-2.35), triglycerides (aHR, 2.14; 95% CI, 1.72-2.67), and inflammatory biomarkers (1.2- to 1.8-fold)-all attenuating with age. Some biomarkers had similar CHD age associations (eg, physical inactivity, lipoprotein[a], total high-density lipoprotein particles), while a few had no association with CHD onset at any age. Most risk factors and biomarkers had associations that attenuated with increasing age at onset. Conclusions and Relevance In this cohort study, diabetes and insulin resistance, in addition to hypertension, obesity, and smoking, appeared to be the strongest risk factors for premature onset of CHD. Most risk factors had attenuated relative rates at older ages.

[1]  Michael J. Pencina,et al.  Quantifying Importance of Major Risk Factors for Coronary Heart Disease , 2018, Circulation.

[2]  Gretchen A. Stevens,et al.  NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4 , 2018, The Lancet.

[3]  R. Vasan,et al.  Epidemiology of cardiovascular disease in young individuals , 2018, Nature Reviews Cardiology.

[4]  Olga V. Demler,et al.  Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women , 2018, Circulation. Genomic and precision medicine.

[5]  R. Collins,et al.  Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke , 2018, Journal of the American College of Cardiology.

[6]  Deepak L. Bhatt,et al.  Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry. , 2017, Journal of the American College of Cardiology.

[7]  Michael R. Kramer,et al.  Widespread recent increases in county-level heart disease mortality across age groups. , 2017, Annals of epidemiology.

[8]  R. Dreyer,et al.  Editor’s Choice-Sex differences in young patients with acute myocardial infarction: A VIRGO study analysis , 2017, European heart journal. Acute cardiovascular care.

[9]  M. Woodward,et al.  Sex differences in risk factor management of coronary heart disease across three regions , 2017, Heart.

[10]  Olga V. Demler,et al.  Lipoprotein insulin resistance score and risk of incident diabetes during extended follow-up of 20 years: The Women's Health Study. , 2017, Journal of clinical lipidology.

[11]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[12]  P. Ridker How Common Is Residual Inflammatory Risk? , 2017, Circulation research.

[13]  J. Manson,et al.  Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality , 2016, PloS one.

[14]  M. Pencina,et al.  Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol , 2016, Journal of the American Heart Association.

[15]  P. Ridker,et al.  Circulating N‐Linked Glycoprotein Side‐Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial , 2016, Journal of the American Heart Association.

[16]  N. Paynter,et al.  Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial. , 2016, JAMA cardiology.

[17]  P. Ridker,et al.  Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. , 2016, Circulation research.

[18]  P. Ridker From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. , 2016, Circulation research.

[19]  G. Maurer,et al.  Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol. , 2015, Journal of clinical lipidology.

[20]  Deepak L. Bhatt,et al.  Temporal Trends and Sex Differences in Revascularization and Outcomes of ST-Segment Elevation Myocardial Infarction in Younger Adults in the United States. , 2015, Journal of the American College of Cardiology.

[21]  V. Vaccarino,et al.  Original Research Put Into Perspective for the Practicing Clinician , 2015 .

[22]  P. Ridker,et al.  Novel Protein Glycan Side-Chain Biomarker and Risk of Incident Type 2 Diabetes Mellitus , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[23]  Tom R. Gaunt,et al.  Metabolite Profiling and Cardiovascular Event RiskCLINICAL PERSPECTIVE , 2015 .

[24]  P. Ouyang,et al.  Age- and sex-related difference in lipid profiles of patients hospitalized with acute myocardial infarction in East China. , 2014, Journal of clinical lipidology.

[25]  L. Cheskin,et al.  Sex differences in short-term and long-term all-cause mortality among patients with ST-segment elevation myocardial infarction treated by primary percutaneous intervention: a meta-analysis. , 2014, JAMA internal medicine.

[26]  Mark A Pereira,et al.  Smoking and risk of coronary heart disease in younger, middle-aged, and older adults. , 2014, American journal of public health.

[27]  P. Ridker,et al.  A Novel Protein Glycan Biomarker and Future Cardiovascular Disease Events , 2014, Journal of the American Heart Association.

[28]  M. Connelly,et al.  Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. , 2014, Metabolic syndrome and related disorders.

[29]  Paul M Ridker,et al.  Anti-inflammatory therapies for cardiovascular disease. , 2014, European heart journal.

[30]  T. Spector,et al.  Lipidomics Profiling and Risk of Cardiovascular Disease in the Prospective Population-Based Bruneck Study , 2014, Circulation.

[31]  K. Lavoie,et al.  Sex-related differences in access to care among patients with premature acute coronary syndrome , 2014, Canadian Medical Association Journal.

[32]  P. Ridker,et al.  Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events , 2014, Circulation.

[33]  J. Singer,et al.  Do younger women fare worse? Sex differences in acute myocardial infarction hospitalization and early mortality rates over ten years. , 2014, Journal of women's health.

[34]  N. Paynter,et al.  High-Density Lipoprotein Particle Subclass Heterogeneity and Incident Coronary Heart Disease , 2014, Circulation. Cardiovascular quality and outcomes.

[35]  A. Khera,et al.  Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin) , 2013, Circulation.

[36]  P. Ridker,et al.  High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy , 2013, Circulation.

[37]  W. Almahmeed,et al.  Age and clinical outcomes in patients presenting with acute coronary syndromes. , 2013, Journal of cardiovascular disease research.

[38]  K. Reddy,et al.  Noncommunicable diseases. , 2013, The New England journal of medicine.

[39]  G. Maurer,et al.  Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (≤ 40 years of age) , 2012, European journal of clinical investigation.

[40]  P. Ridker,et al.  On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). , 2012, Journal of the American College of Cardiology.

[41]  P. Ridker,et al.  Association of High-Density Lipoprotein Cholesterol With Incident Cardiovascular Events in Women, by Low-Density Lipoprotein Cholesterol and Apolipoprotein B100 Levels , 2011, Annals of Internal Medicine.

[42]  D. Preen,et al.  Age- and Sex-Specific Trends in the Incidence of Hospitalized Acute Coronary Syndromes in Western Australia , 2011, Circulation. Cardiovascular quality and outcomes.

[43]  Gretchen A. Stevens,et al.  National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants , 2011, The Lancet.

[44]  K. Kotseva,et al.  EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[45]  Samia Mora,et al.  Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women , 2009, Circulation.

[46]  S. Allender,et al.  Patterns of coronary heart disease mortality over the 20th century in England and Wales: Possible plateaus in the rate of decline , 2008, BMC public health.

[47]  Moyses Szklo,et al.  LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). , 2007, Atherosclerosis.

[48]  N. Cook,et al.  Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. , 2007, JAMA.

[49]  F. Arós,et al.  Characteristics and Outcome of Acute Myocardial Infarction in Young Patients , 2006, Cardiology.

[50]  R. Glynn,et al.  Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. , 2005, American journal of epidemiology.

[51]  J. Manson,et al.  Low-Dose Aspirin in the Primary Prevention of Cancer: The Women’s Health Study: A Randomized Controlled Trial , 2005, JAMA.

[52]  J. Manson,et al.  Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women’s Health Study: A Randomized Controlled Trial , 2005, JAMA.

[53]  J. Manson,et al.  A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women , 2005, The New England journal of medicine.

[54]  Á. Avezum,et al.  Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). , 2005, American heart journal.

[55]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[56]  Ralph B D'Agostino,et al.  Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands , 2004, BMJ : British Medical Journal.

[57]  J. Critchley,et al.  Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. , 2003, JAMA.

[58]  J. De Sutter,et al.  Screening of family members of patients with premature coronary heart disease; results from the EUROASPIRE II family survey. , 2003, European heart journal.

[59]  A. Maggioni,et al.  Epidemiologic Variables and Outcome of 1972 Young Patients With Acute Myocardial Infarction: Data From the GISSI-2 Database , 1997 .

[60]  M. Levin,et al.  The occurrence of lung cancer in man. , 1953, Acta - Unio Internationalis Contra Cancrum.